Rafferty Asset Management
TBPH icon

Rafferty Asset Management’s Theravance Biopharma TBPH Stock Holding History

Rafferty Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,707
Closed -$121K – 1222
2022
Q1 		$121K Buy
+12,707
New +$125K ﹤0.01% 1164
2021
Q4 		– Sell
-12,649
Closed -$94K – 1335
2021
Q3 		$94K Buy
+12,649
New +$141K ﹤0.01% 1233

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rafferty Asset Management's TBPH Position: Q2 2022 in Review

Rafferty Asset Management sold out of Theravance Biopharma (TBPH) in Q2 2022, closing a stake of 12,707 shares — an estimated $121K sold.

Rafferty Asset Management first reported a position in TBPH in Q3 2021 and held it in 2 quarters. The position peaked at $121K in Q1 2022. 113 funds tracked by Wall St. Rank hold TBPH as of Q2 2022.

  • Rafferty Asset Management reported no remaining Theravance Biopharma position as of Q2 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 12,707 Theravance Biopharma shares in Q2 2022, an estimated $121K.
  • Rafferty Asset Management first reported a position in Theravance Biopharma in Q3 2021 and held it in 2 quarters.
  • Rafferty Asset Management's Theravance Biopharma position peaked at $121K in Q1 2022.
  • 113 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2022.

Based on Rafferty Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.